Roche has launched the Elecsys Epstein-Barr Virus (EBV) panel, which consists of Elecsys EBV IgM, Elecsys EBV VCA IgG and Elecsys EBV EBNA IgG immunoassays, in countries accepting the CE Mark.

The panel uses a single blood sample to identify antibodies specific to EBV at various stages of infection.

When used together, the three tests can provide an understanding of how far the infection has progressed in a patient.

Needing a small sample volume of 6μL to 35μL, the immunoassays deliver a result in only 18 minutes.

Roche diagnostics CEO Thomas Schinecker said: “The tests help to provide the information clinicians need to diagnose and treat their patients quickly, effectively reducing the need for further confirmatory testing.”

Roche noted that EBV testing with immunoassays from a blood sample has numerous clinical benefits. EBV is used for confirming the diagnosis of glandular fever in individuals with clinical signs and symptoms while also ruling out other acute diseases with similar clinical pictures.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Furthermore, it is vital to understand the EBV status of donors and recipients in organ and cell transplants, since recipients usually have a weaker immune system.

Routine EBV testing and result analysis can be a strenuous task. Further tests are often needed to detect EBV infection stages, as they are unclear in roughly 5-10% of normal samples.

The Elecsys EBV panel accurately classifies the stage of EBV infection in a high percentage of routine samples, resulting in less confirmatory testing being needed.

This saves time and resources for labs and could aid in better management of patients.

Roche plans to submit an application to the US Food and Drug Administration (FDA) seeking approval for the panel soon.

Last month, the company signed a definitive merger agreement to completely acquire GenMark Diagnostics for a total transaction value of nearly $1.8bn.